Their potency appears to increase with higher baseline HbA1c levels, and in patients with lower baseline HbA1c, GLP-1 RAs may outperform basal insulin—possibly due to suboptimal insulin titration driven by concerns over hypoglycemia [41]. The gene discussed is GLP1R; the disease is Hypoglycemia.